Prolistem - New Azoospermia Treatment

"I Was Told I Have No Stem Cells." Can Prolistem Still Help?

This is an excellent and important question we often hear from patients.
The simple answer is that true complete absence of stem cells (Primary Sertoli Cell-Only Syndrome) is extremely rare. The scientific reality for most men with Non-Obstructive Azoos***mia is far more hopeful.
Here is the truth about

azoos***mia and stem cells:

1. The Science of Hidden Stem Cells
As early as 2010, landmark studies demonstrated the ability to isolate and separate S***matogonial Stem Cells (SSCs) directly from the testicular tissue of patients with NOA. Since then, multiple research teams have confirmed that even in cases of Sertoli Cell-Only Syndrome (SCOS)—where it appears only support cells remain—men often possess hidden, "focal" pockets of dormant stem cells.

2. How Prolistem Works
Prolistem is designed for these common cases. It does not generate stem cells from scratch. Instead, the treatment is formulated to provide the precise nutritional and biological support needed to "awaken" these dormant stem cells and push them forward to complete the process of s***matogenesis (s***m production).

3. The Rare Exception: Primary SCOS
There is a rare, severe form of SCOS where a patient is born completely devoid of any germ cells (complete germ cell aplasia). This is a condition known as Primary SCOS. In this specific, rare scenario, where no stem cells exist to begin with, no currently known treatment or supplement can create s***m.

The Takeaway

For the vast majority of men diagnosed with Azoos***mia, your stem cells are not missing; they are simply unable to finish their journey. Prolistem aims to provide the trigger they need to finally mature.

Another inspiring Prolistem success story shared by Farah Fertility Center.

After a few months of using Prolistem, 250,000 s***m were successfully detected in the semen analysis of a 30-year-old patient diagnosed with azoos***mia.

The patient previously underwent a bilateral testicular biopsy, which showed no s***m found in either the right or left te**is. Hormonal evaluation was within the normal range, including:
• FSH: 5.72
• LH: 7.81
• Testosterone: 11.59

This case highlights that even patients with previous negative biopsy results may still have hope through new treatment strategies and continuous monitoring.

Special thanks to Dr. Faisal Al Omar from Farah Fertility Center for sharing this successful case.

New Research: Does Hormonal Therapy Actually Help Before Micro-TESE?

A new retrospective study weighs in on a highly debated topic in male infertility: the use of empirical hormonal optimization before surgery.

The study evaluated 152 men with non-obstructive azoos***mia (NOA) to determine if a 3-month preoperative regimen of clomiphene citrate and hCG improves surgical outcomes.

The short answer? It did not.

The Key Findings
The s***m retrieval rate (SRR) was 50% for patients who went straight to surgery without hormonal treatment, compared to 45% for those who received the therapy. The difference was not statistically significant.

While the therapy successfully lowered median follicle-stimulating hormone (FSH) levels, it did not significantly alter luteinizing hormone (LH) or total testosterone levels by the time of surgery.

Regardless of hormone therapy, multivariable analysis showed that younger age and higher total testosterone were the actual independent predictors of successful s***m retrieval.

The Big Takeaway
This research aligns closely with current European Association of Urology (EAU) guidelines. It suggests that routine, empirical hormonal optimization before Micro-TESE may not provide the clinical edge many hope for.

Instead, future efforts should focus on better patient stratification to identify the specific subgroups who might truly benefit from targeted stimulation.

***mia

A Journey of Hope and Science: From Non-Obstructive Azoos***mia to Success! 🇦🇿
We are thrilled to share another incredible breakthrough from our Male Reproductive Health Center in Azerbaijan, led by Dr. Abdullah Arman Özdemir.Our 34-year-old patient faced severe Non-Obstructive Azoos***mia (NOA) due to childhood mumps orchitis. His clinical evaluation showed smaller testicular volume and a highly elevated FSH level of 26 mIU/mL, though his genetic analysis was completely normal. Unfortunately, his initial Micro-TESE procedure resulted in no s***matozoa found.Instead of giving up, we initiated a targeted 1-year medical protocol using Prolistem treatment. By the 9th month of therapy, a breakthrough occurred: healthy, viable s***m cells were detected during a specialized s***miogram pellet analysis!

The recovered s***m cells have now been successfully frozen and stored. The next chapter of this miracle will continue in the IVF lab through the ICSI (Intracytoplasmic S***m Injection) method.Never lose hope science and tailored medical treatments can rewrite the story of male infertility.

Another inspiring Prolistem® success story.

A patient diagnosed with non-obstructive azoos***mia (NOA) had:
• FSH: 21.30 mIU/ml
• Testosterone: 2.22 nmol/L
• Previous failed microTESE

After completing six months of Prolistem®, a second microTESE was performed. This time, s***m were successfully found and used for ICSI treatment.

Stories like this continue to give hope to men facing even the most difficult infertility cases. While Prolistem® is not a guarantee, it offers a new strategy and a new opportunity for selected NOA patients.

Big thanks to Alsham Center for sharing this case, especially Dr. Abdul Razzaq Younes and Lab Director Raafat Al-Hindawi. ***mia